drugset / Trial / NCT04494243

A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

NCT04494243

Phase 1 Completed 40 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in healthy volunteers.

Timeline

Start
2020-08-28
Primary completion
2021-01-15
Completion
2021-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-214 Protein / enzyme biologic
Subject Rabeprazole Small molecule 10 mg